🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

850 results for “Elan” Clear

  1. ARC-520

    Arrowhead Pharmaceuticals Ireland Limited

    Healthy

    phase 1 small molecule completed

    2 trials

  2. ARC-521 Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Hepatitis B

    phase 1 small molecule terminated

    1 trial

  3. ARO-AAT Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Alpha 1-Antitrypsin Deficiency

    phase 1 small molecule completed

    1 trial

  4. ARO-ANG3

    Arrowhead Pharmaceuticals Ireland Limited

    Dyslipidemias

    phase 1 small molecule completed

    1 trial

  5. ARO-APOC3

    Arrowhead Pharmaceuticals Ireland Limited

    Hypertriglyceridemia

    phase 1 small molecule completed

    1 trial

  6. ARO-ATXN2 Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Spinocerebellar Ataxia Type 2

    phase 1 small molecule active

    1 trial

  7. ARO-CFB

    Arrowhead Pharmaceuticals Ireland Limited

    IgA Nephropathy

    phase 1 small molecule completed

    1 trial

  8. ARO-HIF2

    Arrowhead Pharmaceuticals Ireland Limited

    Clear Cell Renal Cell Carcinoma

    phase 1 small molecule completed

    1 trial

  9. ARO-RAGE Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Asthma

    phase 1 small molecule completed

    1 trial

  10. ARO-SOD1 Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Amyotrophic Lateral Sclerosis

    phase 1 small molecule terminated

    1 trial

  11. Allo-depleted lymphocyte infusion

    Lxo Ireland Designated Activity Company

    Transplant-Related Hematologic Malignancy

    phase 1 other terminated

    1 trial

  12. Ampreloxetine

    Theravance Biopharma Ireland Umited

    Symptomatic Neurogenic Orthostatic Hypertension

    phase 1 small molecule completed

    1 trial

  13. Ampreloxetine <Dose A>

    Theravance Biopharma Ireland Umited

    Symptomatic Neurogenic Orthostatic Hypertension

    phase 1 small molecule completed

    1 trial

  14. An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Ivacaftor film coated tablets 150 mg of Sun Pharmaceutical Industries Ltd, India with Kalydeco (Ivacaftor) 150 mg film-coated tablets, Marketing Authorisation Holder: Vertex Pharmaceuticals (Ireland) Limited Unit 49, Block F2, Northwood Court, Santry, Dublin 9, D09 T665, Ireland, in healthy adult, human subjects under fed condition.

    Lacuna Pharma Pty Ltd

    Cystic Fibrosis

    phase 1 other active

    1 trial

  15. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Trametinib tablets 2 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with MEKINIST® (Trametinib) tablets 2 mg, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA in healthy, adult, human subjects under fasting condition.

    Lacuna Pharma Pty Ltd

    Adjuvant treatment of BRAF V600E or V600K mutation-positive melanoma (in combination with dabrafenib);, BRAF V600E mutation-positive unresectable or metastatic solid tumors;, BRAF V600E mutation-positive metastatic non-small cell lung cancer (NSCLC), in combination with dabrafenib;, BRAF V600E mutation-positive low-grade glioma (LGG)., BRAF V600E mutation-positive locally advanced or metastatic anaplastic thyroid cancer (ATC);, BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma, as a single agent in BRAF-inhibitor treatment-naïve patients or in combination with dabrafenib;

    phase 1 other active

    1 trial

  16. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Lisdexamfetamine Dimesylate capsules 70 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Elvanse (lisdexamfetamine dimesylate) 70 mg hard capsules, Marketing Authorization Holder: Takeda Pharmaceuticals International AG Ireland Branch, Block 2, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, D02 HW68, Ireland, in healthy adult, human subjects under fas

    Lacuna Pharma Pty Ltd

    ADHD

    phase 1 other active

    1 trial

  17. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Maribavir Tablets 200 mg, manufactured by Sun Pharmaceutical Industries Limited, India with LIVTENCITY® (Maribavir) Coated Tablets 200 mg, manufactured by: Catalent CTS, LLC Kansas City, United States of America, packed by: Takeda Ireland Limited Bray, Ireland, imported by: Takeda Pharma Ltda. Highway SP 340 S/N, km 133.5 Jaguariúna Administrative Building -SP CNPJ 60.397.775/

    Lacuna Pharma Pty Ltd

    cytomegalovirus (CMV) infection and/or disease that is refractory (with or without resistance) to one or more prior therapies in adult patients who have undergone hematopoietic stem cell transplantation (HSCT) or solid organ transplantation (SOT)

    phase 1 other active

    1 trial

  18. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Ponatinib Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Iclusig (Ponatinib hydrochloride) tablets 15 mg, Produced by: Patheon Inc. Mississauga, Canada or Takeda Ireland Limited Bray, Ireland, Imported and registered by: Pint Pharma Medical-Hospital and Pharmaceutical Products Ltd. Nelson Pontes Street, 125, Block 03, Jardim Margarida Zip Code

    Lacuna Pharma Pty Ltd

    chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia

    phase 1 other active

    1 trial

  19. An open-label Phase 1 study of NEO-PTC-01 in patients with advanced or metastatic melanoma

    BioNTech SE

    Metastatic melanoma

    phase 1 other active

    1 trial

  20. Anti-SEMA4D Monoclonal Antibody VX15/2503

    VACCINEX, INC.

    Metastatic Melanoma

    phase 1 mab terminated

    1 trial

  21. Assessment of Pharmacokinetic Similarity of FYB206 in Comparison with Keytruda in Resected Stage II or Stage III Melanoma Patients

    Formycon AG

    Melanoma: Adjuvant treatment of patients with Stage IIB, IIC, or III melanoma following complete resection

    phase 1 other active

    1 trial

  22. Atezolizumab

    Jazz Pharmaceuticals Ireland Limited

    Endometrial Cancer

    phase 1 small molecule active

    1 trial

  23. Autologous Bone Marrow-derived Mononuclear Cells

    Regeneron Ireland Designated Activity Company (DAC)

    Congenital Heart Disease

    phase 1 mab completed

    1 trial

  24. Autologous mononuclear cells

    Regeneron Ireland Designated Activity Company (DAC)

    Congenital Heart Disease, SRV Dependent

    phase 1 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources